| INTRODUCTION
Topical cosmetic products may cause adverse reactions in some people. UK-based research has shown that 57% of women and 31% of men have experienced an adverse reaction to a cosmetic at some stage in their lives, with 23% of women and 14% of men reporting such a reaction in the year prior to the analysis. 1 The most common adverse reactions to cosmetics are irritation, burning sensation, pruritus, and erythema. 2 Sensitive skin may be defined as a noninflammatory response to cosmetics, characterized by stinging, burning, or itching, without visible skin changes. 3 Skin sensitivity is often determined by a stinging test, in which lactic acid or other irritants are applied to the nasolabial fold. 3 People with sensitive skin are likely to develop allergic contact dermatitis or irritation to some cosmetic products. [3] [4] [5] The frequency of self-reported sensitive skin is increasing, with data from a European study 6 and a U.S. study 7 showing that 38% and 45% of subjects, (Table 1) , and who were confirmed to have sensitive skin based on a positive response (prickling, itching, burning, stinging, and/or numbness with an intensity score ≥2) to the lactic acid stinging test 10 at the screening visit, were included. Key exclusion criteria were as follows: the presence of skin marks or active dermatoses in the areas of product application; a history of allergic reactions to topical medications or cosmetics; intense sun exposure or use of tanning equipment within 15 days prior to enrollment or during the study; use of esthetic and/or dermatological treatments in the areas of study product application within 21 days prior to screening or during the study; and therapeutic, topical, or systemic use of immunosuppressants, antihistamines, nonsteroidal anti-inflammatory drugs, or corticosteroids within 14 days (30 days for systemic corticosteroids) prior to screening.
| Study procedures and assessments
The study comprised 2 scheduled clinic visits. At the screening/enrollment visit (Visit 1; Day 1), participants were instructed in the use of the study product by clinical staff and were supplied with a sufficient quantity to enable self-application at home throughout the duration of the study.
Topical application of the study product was performed to the body, including the face, at the discretion of individual participants (reflecting normal use), twice daily for 21 AE 2 days. Throughout this period, participantscompleteda treatmentdiary to recorddaily use of the study product and occurrence of any skin discomfort/sensations. During the study, participants were asked not to apply any product in the experimental area that could interfere with study assessments; change their other cosmetic habits(including hygiene products); perform skin cleansing, exfoliation, or other esthetic treatments in the application area; expose themselves to excessive sunlight/artificial tanning beds; change their eating habits; or changehormonaltreatments.
At the end of the treatment period, participants returned to the clinic (Visit 2; Day 21 AE 2) for final dermatological evaluation and assessment of treatment compliance. Cutaneous acceptability of the study product was determined by evaluation of occurrence of adverse events (local or generalized), skin adverse reactions, and sensations of skin discomfort. Adverse events were defined as any medical occurrence, regardless of causality with the study product, and Specifically, the area of product application was evaluated for the appearance of erythema, edema, and skin desquamation, and scored on a scale ranging from 0 to 4 ( Table 2 ). The intensity of the reaction was calculated as the sum of the scores for the individual components, classified as: 0-2, no reaction/equivocal; 3-4, mild reaction; 5-8, moderate reaction; and >8, intense reaction. Feelings of skin discomfort associated with study product use, including sensations of dryness, prickling, itching, and stinging, were self-recorded by subjects in their treatment diaries; the severity (mild or moderate/intense) and duration (≤15 or >15 minutes) of these events were noted.
| Statistical considerations
No sample size calculation was made. Thirty-five subjects were planned for inclusion to ensure that at least 30 would complete the study. For analysis of product acceptability, only data from subjects with a minimum treatment compliance of 80% (equivalent to a minimum of 30 applications of study product) were considered. All subjects with at least one application of the study product were considered for the safety analysis.
| RESULTS
Thirty-five female subjects underwent screening, all of whom were confirmed eligible to participate in the study. Mean age was 43.2 years (range 20-58 years). The majority of subjects (31/35, 89%) had Fitzpatrick skin phototype I-III (Type I, n = 13; Type II, n = 9; Type III, n = 9; and Type IV, n = 4). All participants completed the study per protocol and achieved the minimum compliance requirement for inclusion in the analysis of study product acceptability.
No adverse events were reported during the study and, per dermatologist clinical evaluation, there were no recorded skin adverse reactions of erythema, edema, or skin desquamation ( Table 3) . None of the 35 participants reported experiencing sensations of skin dryness, prickling, or stinging on any occasion following application of the study product (Table 3) . One participant reported a single experience of mild itching at the site of study product application, which occurred soon after the second application of the day and lasted for approximately 10 minutes. However, as this event was not associated with any clinically apparent skin adverse reaction, resolved spontaneously without treatment, did not interrupt product use by the subject, and did not recur, the investigator determined that the feeling was probably not related to the use of the study product and described the event as a discomfort sensation. There was a single event of mild itching in 1 participant; however, this was of short duration, resolved spontaneously, and was considered probably not related to study product application by the investigator.
| DISCUSSION
This study achieved a high treatment compliance rate; all subjects completed the study, providing safety data based on more than 1000 separate product applications over the course of 3 weeks. The Adapted from the Kligman scale that scores skin desquamation on a scale of 1-3. complete absence of adverse events and skin adverse reactions during the treatment period therefore supports the tolerability of the study product in individuals with sensitive skin. Limitations of the study may include the following: the small sample size and femaleonly subject population, the absence of a control arm and associated treatment blinding, and the conducting of the study at a single center.
Based on the findings of this study, it was concluded that the moisturizing cream was well tolerated under normal conditions of use and is appropriate for topical use by individuals with sensitive skin.
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